See more : Southern Home Medical, Inc. (SHOM) Income Statement Analysis – Financial Results
Complete financial analysis of Immunocore Holdings plc (IMCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunocore Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Akshar Spintex Limited (AKSHAR.BO) Income Statement Analysis – Financial Results
- Lithium Ionic Corp. (LTHCF) Income Statement Analysis – Financial Results
- Planet Communications Asia Public Company Limited (PLANET.BK) Income Statement Analysis – Financial Results
- Autogrill S.p.A. (ATGSY) Income Statement Analysis – Financial Results
- Fourth Dimension Solutions Limited (4THDIM.NS) Income Statement Analysis – Financial Results
Immunocore Holdings plc (IMCR)
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 249.43M | 143.74M | 26.52M | 30.11M | 25.67M | 23.65M |
| Cost of Revenue | 1.04M | 454.00K | 73.23M | 74.81M | 99.99M | 0.00 |
| Gross Profit | 248.39M | 143.28M | -46.71M | -44.70M | -74.32M | 23.65M |
| Gross Profit Ratio | 99.58% | 99.68% | -176.12% | -148.42% | -289.54% | 100.00% |
| Research & Development | 163.55M | 89.17M | 73.23M | 74.81M | 99.99M | 83.58M |
| General & Administrative | 0.00 | 0.00 | 88.40M | 45.74M | 44.18M | 34.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 99.99M | 83.58M |
| SG&A | 144.50M | 93.72M | 88.40M | 45.74M | 44.18M | 34.16M |
| Other Expenses | 0.00 | -3.00K | 57.00K | -1.15M | 185.00K | 5.60M |
| Operating Expenses | 308.04M | 182.89M | 161.68M | 119.40M | 144.17M | 117.73M |
| Cost & Expenses | 309.08M | 183.34M | 161.68M | 119.40M | 144.17M | 117.73M |
| Interest Income | 17.99M | 3.15M | 47.00K | 706.00K | 1.40M | 822.00K |
| Interest Expense | 5.15M | 7.69M | 5.81M | 3.11M | 3.80M | 842.00K |
| Depreciation & Amortization | 4.09M | 5.34M | 7.59M | 8.98M | 9.21M | 6.71M |
| EBITDA | -51.65M | -38.35M | -166.72M | -102.59M | -113.18M | -86.75M |
| EBITDA Ratio | -20.71% | -25.36% | -509.48% | -250.54% | -419.63% | -342.21% |
| Operating Income | -59.65M | -39.61M | -135.16M | -86.19M | -118.32M | -93.46M |
| Operating Income Ratio | -23.91% | -27.56% | -509.66% | -286.22% | -460.95% | -395.09% |
| Total Other Income/Expenses | -1.24M | 5.79M | 33.66M | -1.17M | -7.87M | 5.28M |
| Income Before Tax | -60.89M | -44.15M | -140.93M | -87.36M | -126.19M | -88.18M |
| Income Before Tax Ratio | -24.41% | -30.71% | -531.40% | -290.10% | -491.60% | -372.78% |
| Income Tax Expense | -5.60M | -2.92M | -9.41M | -13.27M | -22.26M | -16.55M |
| Net Income | -55.29M | -41.22M | -131.52M | -74.09M | -103.93M | -71.63M |
| Net Income Ratio | -22.17% | -28.68% | -495.94% | -246.04% | -404.89% | -302.82% |
| EPS | -1.13 | -0.90 | -3.10 | -2.33 | -3.81 | -2.62 |
| EPS Diluted | -1.13 | -0.90 | -3.00 | -2.33 | -3.81 | -2.62 |
| Weighted Avg Shares Out | 48.89M | 45.71M | 42.49M | 31.78M | 27.31M | 27.31M |
| Weighted Avg Shares Out (Dil) | 48.89M | 45.71M | 43.86M | 31.78M | 27.31M | 27.31M |
Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
Is Biotech Immunocore About To Make A 25% Price Move?
IPO Stock Of The Week: Biotech Leader Immunocore Approaches Latest Buy Point
Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock
Immunocore to present at upcoming investor conferences
3 Pharma Stocks That Will Mint Millionaires
IPO Stock Of The Week: Biotech Leader Immunocore Shows New Buy Point
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
Source: https://incomestatements.info
Category: Stock Reports